01/21/22 4:30 PMNYSE, Nasdaq : PFE, OPK Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone DeficiencyPfizer Inc. and OPKO Health, Inc. announced today that the U.S. Food and Drug Administration issued a Complete Response Letter for the Biologics License Application for somatrogon. Pfizer is evaluating the FDA’ s comments and will work with the agency to determine an appropriate path forward. In 2021, Health Canada approved NGENLA ® for the...RHEA-AIneutral
01/14/22 3:30 PMNYSE : PFE fda approvalU.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic DermatitisPfizer Inc. announced today that the United States Food and Drug Administration approved CIBINQO ®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those...RHEA-AIneutral
01/12/22 6:45 AMNYSE : PFE clinical trialcovid-19Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults ReleasedPfizer Inc. today announced positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20™ in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo. “Pfizer is steadfast in its commitment to address...RHEA-AIneutral
01/10/22 6:30 AMNYSE : PFE Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and TherapeuticsPfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle delivery systems to enable messenger RNA- based therapeutics, today announced they have entered into a Development...RHEA-AIvery positive
01/10/22 6:00 AMNYSE, Nasdaq : PFE, BEAM Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare DiseasesPfizer Inc. and Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.RHEA-AIpositive
01/05/22 7:00 AMNYSE : BHVN, PFE Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United StatesBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer'sRHEA-AIpositive
01/05/22 6:45 AMNYSE, Nasdaq : PFE, BNTX Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineThird mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’ s proprietary mRNA technology and on Pfizer’ s antigen technology Clinical trials are expected to...RHEA-AIpositive
01/04/22 11:45 AMNYSE : PFE covid-19Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19Pfizer Inc. announced that the U.S. government has committed to purchasing an additional 10 million treatment courses of its COVID-19 oral therapy, PAXLOVID™. “With the Omicron variant surging, the availability of and accessibility to treatment options is of utmost importance, as millions of people are being diagnosed with COVID-19 each and every day,” said...RHEA-AIneutral
01/04/22 10:00 AMNYSE : PFE conferencesPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 3:00 p.m. Eastern Standard Time. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring...RHEA-AIneutral
01/03/22 9:45 AMNYSE, Nasdaq : PFE, BNTX covid-19Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and OlderFirst emergency use authorization in the United States for a COVID-19 vaccine booster in adolescents 12 through 15 years of age Today’ s FDA action also reduces time between completion of primary series and booster dose for all eligible individuals, and authorizes a third primary series dose for individuals 5 through 11 years of age with certain kinds of...RHEA-AIneutral
